Immunohistochemical study of osteopontin, Ki-67, and CD34 of psoriasis in Mansoura, Egypt

Indian Journal of Pathology and Microbiology

Volumn 55, Issue 1, 2012, Pages 56-60

  Amin, Maha Mohamed ^a   Azim, Zeinab Abdel ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

CD34; Ki 67; osteopontin; psoriasis

Indexed keywords

CD34 ANTIGEN; KI 67 ANTIGEN; OSTEOPONTIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EGYPT; EPIDERMIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; SCHOOL CHILD; SKIN CAPILLARY; SKIN DEFECT; STAINING;

ADOLESCENT; ADULT; ANTIGENS, CD34; CHILD; EGYPT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICROSCOPY; MIDDLE AGED; OSTEOPONTIN; PSORIASIS; SKIN; YOUNG ADULT;

EID: 84860461983     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.94857     Document Type: Article

References (25)

1. Buommino E, Tufano MA, Balato N, Canozo N, Donnarumma M, Gallo L, et al. Osteopontin: A new emerging role in psoriasis. Arch Dermatol Res 2009;301:397-404.
2. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
3. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (Osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4. (Pubitemid 30084330)
4. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-γ and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000;68:495-502.
5. Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006;7:498-506.
6. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129:79-88.
7. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY, et al. Elevated plasma Osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009;60:225-30.
8. Doger FK, Dikicioglu E, Ergin F, Unal E, Sendur N, Uslu M, et al. Nature of cell kinetics in psoriatic epidermis. J Cutan Pathol 2007;34:257-63. (Pubitemid 46239315)
9. Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006;37:861-6. (Pubitemid 43902946)
10. Kawashima K, Doi H, Ito Y, Shibata M, Yoshinaka R, Otsuki Y, et al. Evaluation of cell death and proliferation in psoriatic epidermis. J Dermatol Sci 2004;35:207-14. (Pubitemid 39295695)
11. Mobini N, Toussaint S, Kamino H. Psoriasis. In: Lever's Histopathology of the Skin (Elder DE, Elenitsas R, Johnson BL Jr, Murphy GF, editors. 10 th ed. Philadelphia, PA; Lippincott Williams and Wilkins; 2009. p. 174-81.
12. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, et al. Papilloma development is delayed in Osteopontin-null mice: Implicating an antiapoptosis role for Osteopontin. Cancer Res 2006;66:7119-27. (Pubitemid 44197689)
13. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ, et al. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997;151:1321-9. (Pubitemid 27479762)
14. Koçak M, Bozdogan O, Erkek E, Atasoy P, Birol A. Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis. Int J Dermatol 2003;42:789-93. (Pubitemid 37304042)
15. Wang KX, Denhardt DT. Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008;19:333-45.
16. Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation towards a Th-1 polarizing phenotype. Blood 2005;106:946-55. (Pubitemid 41076439)
17. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61. (Pubitemid 32422899)
18. Jun-min Z, Geng-shi H, Chun-hong Z. Expression of P57 (kip2), PCNA and Ki67 in psoriatic lesion. J Chin Trop Med 2009;9:453.
19. Gudjonsson JE, Johnston A, Sígmundsdottír H, Valdímarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:257-63.
20. Walsh DS, Borke JL, Balagon MV. Psoriasis is characterized by altered epidermal expression of caspase 14, a novel regulator of keratinocyte terminal differentiation and barrier formation. J Dermatol Sci 2005;37:61-3. (Pubitemid 40037582)
21. Kerkhof P. Texbook of psoriasis. Oxford: Blackwell Publishing Ltd.; 2003. p. 83-109.
22. Nickoloff BJ, Griffiths CE. Lymphocyte trafficking in Psoriasis: A New Perspective Emphasizing the Dermal Dendrocyte with Active Dermal Recruitment Mediated via Endothelial Cells Followed by Intra-Epidermal T-Cell Activation. J Investig Dermatol 1990;95:35S-7S.
23. Gürsoy G, Acar Y, Alagöz S. Osteopontin: A multifunctional molecule. J Med Med Sci 2010;1:55-60.
24. Giachelli CM, Steitz S. Osteopontin: A versatile regulator of inflamation and biomineralization. Matrix Biol 2000;19:615-22.
25. Konno S, Kurokawa M, Uede T, Nishimura M, Huang SK. Role of Osteopontin, a multifunctional protein, in allergy and asthma. Clin Exp Allergy 2011;7:93-109.